. Author manuscript; available in PMC: 2018 Aug 20.

Published in final edited form as: Drug Dev Ind Pharm. 2017 May 19;43(9):1391–1401. doi: 10.1080/03639045.2017.1313861

Table 1.

Co-delivery of miRNA, miRNA inhibitor, or plasmid DNA with other cancer therapeutic agents via nanoparticles

Nanoparticle	miRNA/pDNA/ Inhibitor	Co-delivered Therapeutic	Target Cancer	Reference
Methoxy poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylenecarbonate-graft-dodecanol-graft-tetraethylene-pentamine): micelle	miR-let7B	GDC-0449-Hedgehog signaling inhibitor	Pancreatic ductal adenocarcinoma	[104]
GC4 svFv-liposome-polycation-hyaluronic acid (LPH) nanoparticle	miR-34a	siRNAs (c-Myc, MDM2, VEGF)	Lung metastasis of murine B16F10 melanoma	[105]
Chitosan-coated polylactic acid nanoparticle	Proteasome Beta subunit 5 (β5) pDNA	Cisplatin, P62 siRNA	Ovarian cancer cells	[24]
Mesoporous silica nanoparticle	Model single strand DNA (ssDNA)	Doxorubicin	HeLa cells	[106]
PAMAM modified NIR-responsive hollow gold nanoparticle	miR-21 inhibitor	Doxorubicin	Breast cancer cells and breast cancer stem cells.	[107]
Hyaluronic acid-coated PEI-PLGA nanoparticle	miR-542-3p	Doxorubicin	Triple negative breast cancer (MDA-MB-231)	[108]
Solid lipid nanoparticle	Plasmid EGFP (model DNA)	Doxorubicin	NSCLC cells/tumor: A549	[109]
Cationic core-shell nanoparticle	IL-12 pDNA or BCL-2 siRNA	Paclitaxel	4T1 mouse breast cancer model	[110]
Heparin–Biotin/Heparin/C_alcium carbonate/Calcium Phosphate	p53 pDNA	Doxorubicin	HeLa cells	[111]
Calcium Phosphate polymer hybrid nanoparticles	miR-221/222 Inhibitors	Paclitaxel	Triple-negative breast cancer (MDA-MB-231)	[112]
Alginate/Calcium carbonate hybrid nanoparticles	p53 pDNA	Doxorubicin	HeLa cells	[113]